Highly sensitive simultaneous quantification of indoxyl sulfate and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid in human plasma using ultra-high-performance liquid chromatography coupled with tandem mass spectrometry.

Tytuł:: Highly sensitive simultaneous quantification of indoxyl sulfate and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid in human plasma using ultra-high-performance liquid chromatography coupled with tandem mass spectrometry.
Autorzy:: Oda A; Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Kiyose, Japan.
Suzuki Y; Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Kiyose, Japan.
Sato B; Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Kiyose, Japan.
Sato H; Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Kiyose, Japan.
Tanaka R; Department of Clinical Pharmacy, Oita University Hospital, Yufu, Japan.
Ono H; Department of Clinical Pharmacy, Oita University Hospital, Yufu, Japan.
Ando T; Department of Urology, Oita University Faculty of Medicine, Yufu, Japan.
Shin T; Department of Urology, Oita University Faculty of Medicine, Yufu, Japan.
Mimata H; Department of Urology, Oita University Faculty of Medicine, Yufu, Japan.
Itoh H; Department of Clinical Pharmacy, Oita University Hospital, Yufu, Japan.
Ohno K; Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Kiyose, Japan.
Źródło:: Journal of separation science [J Sep Sci] 2022 May; Vol. 45 (10), pp. 1672-1682. Date of Electronic Publication: 2022 Mar 11.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Original Publication: Weinheim, Germany : Wiley-VCH, c2001-
MeSH Terms:: Tandem Mass Spectrometry*/methods
Uremia*
Chromatography, High Pressure Liquid/methods ; Furans ; Humans ; Indican ; Pharmaceutical Preparations ; Propionates
References:: Prueksaritanont T, Tatosian DA, Chu X, Railkar R, Evers R, Chavez-Eng C, Lutz R, Zeng W, Yabut J, Chan GH, Cai X, Latham AH, Hehman J, Stypinski D, Brejda J, Zhou C, Thornton B, Bateman KP, Fraser I, Stoch SA, S A. Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A. Clin Pharmacol Ther. 2017;101:519-30.
Hohmann N, Haefeli WE, Mikus G. CYP3A activity: towards dose adaptation to the individual. Expert Opin Drug Metab Toxicol. 2016;12:479-97.
Klein K, Zanger UM. Pharmacogenomics of cytochrome P450 3A4: recent progress toward the “Missing Heritability” problem. Front Genet. 2013;4:12.
Ieiri I, Takane H, Hirota T, Otsubo K, Higuchi S. Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy. Expert Opin Drug Metab Toxicol. 2006;2:651-74.
Leblond F, Guevin C, Demers C, Pellerin I, Gascon-Barre M, Pichette V. Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol. 2001;12:326-32.
Guevin C, Michaud J, Naud J, Leblond FA, Pichette V. Down-regulation of hepatic cytochrome p450 in chronic renal failure: role of uremic mediators. Br J Pharmacol. 2002;137:1039-46.
Naud J, Michaud J, Beauchemin S, Hebert MJ, Roger M, Lefrancois S, Leblond FA, Pichette V. Effects of chronic renal failure on kidney drug transporters and cytochrome P450 in rats. Drug Metab Dispos. 2011;39:1363-9.
Nolin TD, Frye RF, Le P, Sadr H, Naud J, Leblond FA, Pichette V, Himmelfarb J. ESRD impairs nonrenal clearance of fexofenadine but not midazolam. J Am Soc Nephrol. 2009;20:2269-76.
Thomson BK, Nolin TD, Velenosi TJ, Feere DA, Knauer MJ, Asher LJ, House AA, Urquhart BL. Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms. Am J Kidney Dis. 2015;65:574-82.
Sun H, Huang Y, Frassetto L, Benet LZ. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos. 2004;32:1239-46.
Hanada K, Ogawa R, Son K, Sasaki Y, Kikkawa A, Ichihara S, Ogata H. Effects of indoxylsulfate on the in vitro hepatic metabolism of various compounds using human liver microsomes and hepatocytes. Nephron Physiol. 2006;103:179-86.
Fujita K, Sugiura T, Okumura H, Umeda S, Nakamichi N, Watanabe Y, Suzuki H, Sunakawa Y, Shimada K, Kawara K, Sasaki Y, Kato Y. Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for SN-38, an active metabolite of irinotecan, in humans. Pharm Res. 2014;31:204-15.
Suzuki Y, Itoh H, Fujioka T, Sato F, Kawasaki K, Sato Y, Sato Y, Ohno K, Mimata H, Kishino S. Association of plasma concentration of 4beta-hydroxycholesterol with CYP3A5 polymorphism and plasma concentration of indoxyl sulfate in stable kidney transplant recipients. Drug Metab Dispos. 2014;42:105-10.
Patki KC, Von Moltke LL, Greenblatt DJ. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003;31:938-44.
Kamdem LK, Streit F, Zanger UM, Brockmoller J, Oellerich M, Armstrong VW, Wojnowski L. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin. Chem. 2005;51:1374-81.
Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, Shen DD, Thummel KE. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab. Dispos. 2006;34:836-47.
Nakanishi T, Tamai I. Genetic polymorphisms of OATP transporters and their impact on intestinal absorption and hepatic disposition of drugs. Drug Metab Pharmacokinet. 2012;27:106-21.
DeGorter MK, Tirona RG, Schwarz UI, Choi YH, Dresser GK, Suskin N, Myers K, Zou G, Iwuchukwu O, Wei WQ, Wilke RA, Hegele RA, Kim RB. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet. 2013;6:400-8.
Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum M, Kivisto KT, Neuvonen PJ. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005;77:468-78.
Niemi M, Kivisto KT, Hofmann U, Schwab M, Eichelbaum M, Fromm MF. Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol. 2005;59:602-4.
Itoh Y, Ezawa A, Kikuchi K, Tsuruta Y, Niwa T. Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production. Anal Bioanal Chem. 2012;403:1841-50.
Fabresse N, Uteem I, Lamy E, Massy Z, Larabi IA, Alvarez JC. Quantification of free and protein bound uremic toxins in human serum by LC-MS/MS: comparison of rapid equilibrium dialysis and ultrafiltration. Clin Chim Acta. 2020;507:228-35.
Andre C, Bennis Y, Titeca-Beauport D, Caillard P, Cluet Y, Kamel S, Choukroun G, Maizel J, Liabeuf S, Bodeau S. Two rapid, accurate liquid chromatography tandem mass spectrometry methods for the quantification of seven uremic toxins: an application for describing their accumulation kinetic profile in a context of acute kidney injury. J Chromatogr B Analyt Technol Biomed Life Sci. 2020;1152:122234.
Boelaert J, Lynen F, Glorieux G, Eloot S, Van Landschoot M, Waterloos MA, Sandra P, Vanholder R. A novel UPLC-MS-MS method for simultaneous determination of seven uremic retention toxins with cardiovascular relevance in chronic kidney disease patients. Anal Bioanal Chem. 2013;405:1937-47.
Wang Z, Jiang H, Chen X, Song X, Xu F, Chen F, Mao Z, Gao S, Chen W. A rapid and sensitive method for simultaneous determination of eight protein-bound uremic toxins in human serum by UHPLC-MS/MS: application in assessing peritoneal dialysis. J Pharm Biomed Anal. 2020;186:113312.
Suzuki Y, Sasamoto Y, Yoshijima C, Tanaka R, Ono H, Ando T, Shin T, Mimata H, Itoh H, Ohno K. Simultaneous quantification of coproporphyrin-I and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid in human plasma using ultra-high performance liquid chromatography coupled to tandem mass spectrometry. J Pharm Biomed Anal. 2020;184:113202.
Japanese Society of Nephrology. Evidence-based clinical practice guideline for ckd 2013. Clin Exp Nephrol. 2014;18:346-423.
Suzuki Y, Sato M, Awazuhara T, Nukui Y, Yoshida A, Terashima T, Watanabe K, Fujioka R, Tsuchihara K, Kishino S, Ohno K. Simultaneous quantification of arctigenin and its glucuronide conjugate in mouse plasma using ultra-high performance liquid chromatography coupled to tandem mass spectrometry. J Sep Sci. 2021;44:1299-306.
Food and Drug Administration. Bioanalytical method validation guidance for industry. US Department of Health and Human Services. 2018. https://www.fda.gov/media/70858/download Accessed Feb 12, 2021.
Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W. European uremic toxin work group, Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003;63:1934-43.
Meert N, Schepers E, De Smet R, Argiles A, Cohen G, Deppisch R, Drueke T, Massy Z, Spasovski G, Stegmayr B, Zidek W, Jankowski J, Vanholder R. Inconsistency of reported uremic toxin concentrations. Artif Organs. 2007;31:600-11.
Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A, European Uremic Toxin Work Group. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012;23:1258-70.
Contributed Indexing:: Keywords: chronic kidney disease; cytochrome P450 3A; drug transporter; indoxyl sulfate; mass spectrometry
Substance Nomenclature:: 0 (3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid)
0 (Furans)
0 (Pharmaceutical Preparations)
0 (Propionates)
N187WK1Y1J (Indican)
Entry Date(s):: Date Created: 20220305 Date Completed: 20220524 Latest Revision: 20220524
Update Code:: 20240105
DOI:: 10.1002/jssc.202100950
PMID:: 35247297
: Czasopismo naukowe

Pełny tekst

Indoxyl sulfate and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid are uremic toxins that accumulate in renal failure and have been reported to decrease the activities of the drug-metabolizing enzyme cytochrome P450 3A and the drug transporter organic anion transporting polypeptides 1B, respectively. In this study, we established and validated an assay for simultaneous quantification of indoxyl sulfate and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid in human plasma. The samples were pretreated by solid-phase extraction, and measured by ultra-high-performance liquid chromatography-tandem mass spectrometry. The validation results for this assay were within the acceptable limits recommended by the US Food and Drug Administration, with a lower limit of quantitation of 0.05 μg/mL for both indoxyl sulfate and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid. Recovery rates of indoxyl sulfate and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid corrected by internal standard were 100.7-101.9 and 100.2-101.3%, respectively. Matrix effects of indoxyl sulfate and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid corrected by internal standard were 101.1-105.5 and 97.0-103.8%, respectively. The validated assay was used to analyze indoxyl sulfate and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid concentrations in the plasma samples of healthy volunteers and patients with chronic kidney disease. All the measured plasma indoxyl sulfate and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid concentrations were within the calibration ranges. This novel method may contribute to predicting the activities of drug-metabolizing enzymes and drug transporters in individual patients.
(© 2022 Wiley-VCH GmbH.)

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja